Time to clinically meaningful improvement in QLDS
Figure 4 · Panel Figure_4A
Panel Figure_4A 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Andreas Reif, Bernhard T Baune, Jozefien Buyze, Anthony J Cleare, Shaun Johnson, Yerkebulan Kambarov, Nigel Olisa, Falk Schuster, Christian von Holt, Tamara Werner-Kiechle, Eduard Vieta
Eur Psychiatry 68(1) e156
BACKGROUND: Clinical response and remission may not fully reflect patient priorities in treatment-resistant depression (TRD). Health-related quality-of-life (HRQoL) outcomes should be assessed to comprehensively capture treatment benefits. METHODS: ESCAPE-TRD (NCT04338321) was a 32-week randomized, phase IIIb trial comparing esketamine nasal spray (NS) versus quetiapine extended release (XR), both alongside an ongoing selective serotonin reuptake inhibitor/serotonin-norepinephrine reuptake inhibitor, in patients with TRD. Symptom and HRQoL improvements were assessed using the Patient Health Questionnaire-9 (PHQ-9), 36-Item Short Form Survey (SF-36), Quality of Life in Depression Scale (QLDS), and EuroQoL 5-Dimension 5-Level (EQ-5D-5L) measures. RESULTS: Esketamine NS-treated patients (N=336) reached PHQ-9 remission (score ≤4) quicker than quetiapine XR-treated patients (N=340), and more had remission by Week 32 (34.5% vs. 18.2%; odds ratio [OR]: 2.39 [1.67, 3.41], p<0.0001). "Role Emotional", "Mental Health", and "Social Functioning" SF-36 domains showed significantly greater improvements in esketamine NS-treated patients compared with quetiapine XR-treated patients at Week 32 (p<0.05), returning to levels close to general population norms. More esketamine NS-treated patients had a meaningful improvement in their QLDS score by Week 32 (60.7% vs. 41.8%; OR: 2.16 [1.59, 2.94], p<0.0001), and reached this improvement quicker than quetiapine XR-treated patients. Proportions of patients reporting an EQ-5D-5L score of 1 (no problems) were significantly higher across all domains with esketamine NS versus quetiapine XR at Week 32 (p<0.05). CONCLUSIONS: Esketamine NS produced superior improvements in HRQoL compared with quetiapine XR, indicating positive impacts on aspects of patients' lives that matter to them, alongside clinical symptoms of TRD.
1 个 Figure · 1 个 KM 面板
Figure 4. Time to a clinically meaningful improvement in QLDS. Full analysis set (includes all randomized patients). Patients discontinuing treatment were censored at an infinite (arbitrarily large) time and were assumed to never achieve clinically meaningful improvement. Time to first clinically meaningful improvement was defined as the first time a QLDS reduction of ≥8 points was reached. Shaded areas indicate 95% CIs. (A) Tested at a two-sided 0.05 significance level without adjustment for multiple testing. CI, confidence interval; ESK, esketamine; HR, hazard ratio; NS, nasal spray; QLDS, Quality of Life in Depression Scale; QTP, quetiapine; XR, extended release.
Figure 4 · Panel Figure_4A
Panel Figure_4A 是同一 Figure 4 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。